Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness
The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with severe/very severe COVID-19 illness.
The patient’s Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
Condition or disease: severe/very severe COVID-19 illness. Intervention/treatment: Drug Ruxolitinib (Jakavi)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff. For general information, Learn About Clinical Studies.
Criteria for inclusion/exclusion and further details about this trial
Full details for this trial can be found here…
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04337359